企業を読み込み中
Keep exploring
The themes Indivior Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited$34.4BA
NBIXNeurocrine Biosciences, Inc.$16.9BA+
ELANElanco Animal Health Incorporated$13.4BA
KNSAKiniksa Pharmaceuticals International, plc$8.2BA+
LQDALiquidia Corporation$5.2BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026年10月28日CAGraded C, now A
どうやって稼いでいるか
- SUBLOCADE monthly buprenorphine injections74%
- Sublingual buprenorphine medicines25%
売上構成比はsix months ended June 30, 2026の推計であり、提出された報告書の数字ではありません。
競合
- CAMXCamurus
- Braeburn
- ALKSAlkermesC
- 規模
- $7.9B
- 利益率
- -0.0%
何を売っているか4
SUBLOCADE
An extended-release buprenorphine injection given under the skin once a month by a health care professional to treat OUD.
SUBOXONE Film
A film containing buprenorphine and naloxone that dissolves under the tongue or against the inside of the cheek to treat OUD.
SUBUTEX Tablet
A buprenorphine tablet that dissolves under the tongue to treat OUD; sold mainly in Australia, France and Germany.
SUBOXONE Tablet
A buprenorphine-and-naloxone tablet for OUD that Indivior continues to sell on a limited transition basis in some countries.
誰が買っているか4
- Pharmaceutical wholesalers buy medicines from Indivior and distribute them to pharmacies, hospitals and other health care customers; its three largest customers together accounted for 51% of global net revenue (2025, high).
- Specialty pharmacies and distributors handle medicines that require controlled storage or delivery, including SUBLOCADE.
- Hospitals, addiction treatment centers and other organized health systems purchase or arrange access to medicines for patients receiving care.
- Government and private health insurers reimburse for treatment, while health care professionals prescribe or administer the medicines.
何に支えられ、何に崩されうるか
事業が頼っているもの
- 1SUBLOCADE accounted for 74% of net revenue (six months ended June 30, 2026, high), making sales dependent on that product.
- 2The United States accounted for 85% of net revenue (2025, high).
- 3Indivior makes the buprenorphine active ingredient at its Hull, United Kingdom plant, but relies on Curia to manufacture SUBLOCADE.
- 4Aquestive is the exclusive global manufacturer and primary packager of SUBOXONE Film.
- 5The three largest U.S. wholesale customers accounted for 51% of global net revenue (2025, high).
うまくいかなくなる可能性
- 1Sales depend heavily on SUBLOCADE; competing long-acting buprenorphine medicines and generic competition for other products could reduce sales or put pressure on prices.
- 2Reliance on outside manufacturers and packagers creates a risk that production or regulatory problems could interrupt supply; buprenorphine supply also depends on controlled-substance import and distribution rules.
- 3Changes to insurance coverage, government reimbursement or rules for controlled medicines could limit patient access or reduce what Indivior receives for its medicines.
Indivior Pharmaceuticals, Inc.について
Indivior makes prescription medicines for opioid use disorder (OUD), a condition involving harmful opioid use. Its main product, SUBLOCADE, is a monthly injection given by a health care professional; other medicines dissolve under the tongue or inside the cheek. The company sells mainly in the United States, with sales also in Canada, Australia, France and Germany.
- 本社
- Richmond, Virginia, United States
- 設立
- 2014
- 上場市場
- Nasdaq
- 決算期
- December 31
Indivior Pharmaceuticals, Inc. 自身が米国証券取引委員会（SEC）に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。 これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。
